Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study

Table 3 Retention rate and cause-specific retention rate during IL-6 receptor inhibitor therapy^a

Outcome	Analysis	Hazard ratio (95% CI)
Outcome	Analysis	SAR-SC 200 mg biweekly vs. TCZ-SC 162 mg biweekly	TCZ-IV 8 mg/kg every 4 weeks vs. TCZ-SC 162 mg biweekly
Retention rate	Unweighted	1.16 (0.80 to 1.69)	1.20 (0.86 to 1.67)
	Weighted	1.13 (0.72 to 1.77)	1.25 (0.84 to 1.84)
Cause-specific retention rate^b
Lack of effectiveness	Weighted	1.12 (0.64 to 1.93)	0.69 (0.39 to 1.22)
Adverse event	Weighted	1.20 (0.59 to 2.42)	2.51 (1.45 to 4.34)

Abbreviations: CI, confidence interval; IV, intravenous; SAR, sarilumab; SC, subcutaneous; TCZ, tocilizumab
When 1 for hazard ratio is not contained within the 95% CI, the p-value is < 0.05
^aResults stem from Cox proportional hazard model analyses
^bCause-specific retention rate for remission was not determined because of the low incidence rate

ISSN: 1478-6362